Study protocol for two randomised controlled trials evaluating the effects of Cerclage in the reduction of extreme preterm birth and perinatal mortality in twin pregnancies with a short cervix or dilatation: The TWIN Cerclage studies
Van Gils, Lissa; De Boer, Marjon A.; Bosmans, Judith; Duijnhoven, Ruben; Schoenmakers, Sam; Derks, Jan B.; Prins, Jelmer R.; Al-Nasiry, Salwan; Lutke Holzik, Margo; Lopriore, Enrico; Van Drongelen, Joris; Knol, Marieke H.; Van Laar, Judith O.E.H.; Jacquemyn, Yves; Van Holsbeke, Caroline; Dehaene, Isabelle; Lewi, Liesbeth; Van Der Merwe, Hannes; Gyselaers, Wilfried; Obermann-Borst, Sylvia A.; Holthuis, Mayella; Mol, Ben W.; Pajkrt, Eva; Oudijk, Martijn A.
(2024) BMJ Open, volume 14, issue 5
(Article)
Abstract
Introduction Twin pregnancies have a high risk of extreme preterm birth (PTB) at less than 28 weeks of gestation, which is associated with increased risk of neonatal morbidity and mortality. Currently there is a lack of effective treatments for women with a twin pregnancy and a short cervix or cervical
... read more
dilatation. A possible effective surgical method to reduce extreme PTB in twin pregnancies with an asymptomatic short cervix or dilatation at midpregnancy is the placement of a vaginal cerclage. Methods and analysis We designed two multicentre randomised trials involving eight hospitals in the Netherlands (sites in other countries may be added at a later date). Women older than 16 years with a twin pregnancy at <24 weeks of gestation and an asymptomatic short cervix of ≤25 mm or cervical dilatation will be randomly allocated (1:1) to both trials on vaginal cerclage and standard treatment according to the current Dutch Society of Obstetrics and Gynaecology guideline (no cerclage). Permuted blocks sized 2 and 4 will be used to minimise the risk of disbalance. The primary outcome measure is PTB of <28 weeks. Analyses will be by intention to treat. The first trial is to demonstrate a risk reduction from 25% to 10% in the short cervix group, for which 194 patients need to be recruited. The second trial is to demonstrate a risk reduction from 80% to 35% in the dilatation group and will recruit 44 women. A cost-effectiveness analysis will be performed from a societal perspective. Ethics and dissemination This study has been approved by the Research Ethics Committees in the Netherlands on 3/30/2023. Participants will be required to sign an informed consent form. The results will be presented at conferences and published in a peer-reviewed journal. Participants will be informed about the results.
show less
Download/Full Text
Keywords: fetal medicine, maternal medicine, obstetrics, General Medicine
ISSN: 2044-6055
Publisher: BMJ Publishing Group
Note: Publisher Copyright: © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
(Peer reviewed)